Spots Global Cancer Trial Database for Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer
Official Title: A Randomized, Double Blinded, Placebo Controlled Multicenter Phase III Study of Apatinib Mesylate Tablets in the Treatment of Advanced or Metastatic Gastric Cancer
Study ID: NCT01512745
Conditions
Study Description
Brief Summary: Apatinib is a tyrosin-inhibitor agent targeting at vascular endothelial growth factor receptor (VEGFR), and it's anti-angiogenesis effect has been viewed in preclinical tests. The investigators' phase I study has shown that the drug's toxicity is manageable and the maximum tolerable daily dose is 850 mg. The purpose of this study is to determine whether apatinib can improve progression free survival or overall survival compared with placebo in patients with metastatic gastric carcinoma who failed two lines of chemotherapy.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The 81 Hosiptal of PLA, Nanjing, Jiangsu, China
Fudan University cancer hospital, Shanghai, Shanghai, China
Contact Details
Name: Jin Li, MD, PHD
Affiliation: Fudan University
Role: PRINCIPAL_INVESTIGATOR
Name: Shukui Qin, MD
Affiliation: The 81 Hospital of PLA
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
